drugset
drugset / Trial / NCT00620100

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

NCT00620100 ↗

Phase 2 Terminated 2 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin or doxorubicine) followed by 4 cycles of docetaxel single agent. To determine the Time to Tumor Progression (TTP), the Response Duration, the Overall Survival. To confirm the safety profile

Timeline

Start
2004-09
Primary completion
2005-04
Completion
2005-04

Outcome

Outcome not reported

Stopped (Enrollment): “the study was early terminated due to lack of recruitment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — —

Indications

breast neoplasm